Why Is Biodexa Pharmaceuticals (BDRX) Up 56% Today?

Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is rocketing higher on Thursday after announcing additional positive results from a Phase 2 clinical trial. According to the company, results from its study of eRapa are going well. This is its treatment candidate for Familial Adenomatous Polyposis (FAP). That's a mostly inherited condition that increases the risk of developing colorectal cancer. Results from 12 months of study show a median 17% decrease in overall polyp burden. It also showed an overall non-progr ...